• Clinical Evidence

Guardian of Glucose, Consider Using an Electronic Algorithm to Achieve Postcardiac Surgery Glycemic Control

Setting: 800-bed hospital, Level II trauma center and regional referral center for tertiary and quaternary care.

Objective

This prospective study compares post-operative glycemic control for cardiac surgery patients before and after implementation of a software-based tool for insulin dosing (EndoTool).

Setting

800-bed hospital, Level II trauma center and regional referral center for tertiary and quaternary care.

Results

  • Time to control in the cardiovascular recovery unit decreased 78% with EndoTool, from 9 hours to just over 2 hours.
  • Percentage of CABG patients who achieved the optimal blood glucose range of 71-150 mg/dL in the cardiovascular intensive care unit more than quadrupled with EndoTool, from 17% to 91.5%.
  • Mean average incidence of hypoglycemia <70 mg/dL decreased 84% with EndoTool, from 3% to 0.48% of blood glucose measurements.

Conclusions

There is overwhelming evidence that a software-based tool for insulin dosing (EndoTool) improves glycemic control for cardiac surgery patients; additional benefits include projected cost savings from decreased length of stay and mortality as well as overall simplicity of use, ability to customize based on service line/patient population, and user support.
Objective

This prospective study compares post-operative glycemic control for cardiac surgery patients before and after implementation of a software-based tool for insulin dosing (EndoTool).

Setting

800-bed hospital, Level II trauma center and regional referral center for tertiary and quaternary care.

Results
  • Time to control in the cardiovascular recovery unit decreased 78% with EndoTool, from 9 hours to just over 2 hours.
  • Percentage of CABG patients who achieved the optimal blood glucose range of 71-150 mg/dL in the cardiovascular intensive care unit more than quadrupled with EndoTool, from 17% to 91.5%.
  • Mean average incidence of hypoglycemia <70 mg/dL decreased 84% with EndoTool, from 3% to 0.48% of blood glucose measurements.
Conclusions

There is overwhelming evidence that a software-based tool for insulin dosing (EndoTool) improves glycemic control for cardiac surgery patients; additional benefits include projected cost savings from decreased length of stay and mortality as well as overall simplicity of use, ability to customize based on service line/patient population, and user support.

References

Authors

Craig Harris, RN, BSN, MPH; Dawn Greene, RN, CCRN, CS.

Source

Published in Nursing Management, Volume 40, Issue 5, p18-22.

Year

2009

Quick navigation
Objective
Setting
Results
Conclusions
References
Objective

This prospective study compares post-operative glycemic control for cardiac surgery patients before and after implementation of a software-based tool for insulin dosing (EndoTool).

Setting

800-bed hospital, Level II trauma center and regional referral center for tertiary and quaternary care.

Results
  • Time to control in the cardiovascular recovery unit decreased 78% with EndoTool, from 9 hours to just over 2 hours.
  • Percentage of CABG patients who achieved the optimal blood glucose range of 71-150 mg/dL in the cardiovascular intensive care unit more than quadrupled with EndoTool, from 17% to 91.5%.
  • Mean average incidence of hypoglycemia <70 mg/dL decreased 84% with EndoTool, from 3% to 0.48% of blood glucose measurements.
Conclusions

There is overwhelming evidence that a software-based tool for insulin dosing (EndoTool) improves glycemic control for cardiac surgery patients; additional benefits include projected cost savings from decreased length of stay and mortality as well as overall simplicity of use, ability to customize based on service line/patient population, and user support.

References

Authors

Craig Harris, RN, BSN, MPH; Dawn Greene, RN, CCRN, CS.

Source

Published in Nursing Management, Volume 40, Issue 5, p18-22.

Year

2009

Short and Sweet Headlines are Best!

Related posts

Image
  • Clinical Evidence

Near Elimination of Severe Hypoglycemia with EndoTool IV Across a 19-Hospital Health System

Near Elimination of Severe Hypoglycemia with EndoTool IV Across a 19-Hospital Health System

To evaluate the impact of EndoTool IV insulin dosing software on reducing severe hypoglycemia (SH) (blood glucose < 40 mg/dL) across 19-hospitals at a prominent health system, including outcomes in patients with renal insufficiency.
Image
  • Clinical Evidence

Temple Health Achieves Zero Severe Hypoglycemia in Renally Impaired Patients with EndoTool SubQ

Temple Health Achieves Zero Severe Hypoglycemia in Renally Impaired Patients with EndoTool SubQ

To evaluate the safety and efficacy of the EndoTool SubQ (ETSQ) insulin dosing application for subcutaneous (SQ) insulin administration in hospitalized patients, and to compare clinical outcomes against those treated using a standard insulin order set. The analysis also examined performance in high-risk patients with advanced renal impairment.
Image
  • Clinical Evidence

Improving Inpatient Glycemic Safety at Temple Health with EndoTool SubQ

Improving Inpatient Glycemic Safety at Temple Health with EndoTool SubQ

Temple Health, a 3-hospital academic system was experiencing high rates of hypoglycemia due to reliance on sliding scale insulin (SSI). To improve safety and align with ADA guidelines, the hospital implemented EndoTool SubQ, a patient-specific insulin dosing software the supports four dosing protocols, including basal-bolus-correction (BBC).
Get in Touch

Ready to get started?

Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name*
By submitting this form, you consent to the processing of your personal information, including sensitive personal information you provide, in accordance with the Monarch Medical Technologies Privacy Notice.